BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obinutuzumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Obinutuzumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03980171-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03980171)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Follicular Lymphoma.\nStudy: Study o
 f Lenalidomide\, Venetoclax and Obinutuzumab in Patients With Treatment-Na
 ïve Follicular Lymphoma\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03980171
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895436-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study to Assess Change in Disease Activity and Adverse Events of Oral Vene
 toclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recur
 ring Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04895436
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295770-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06295770)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab in Treatment of Fi
 brillary Glomerulonephritis\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06295770
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02393157-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02393157)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02393157
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06549335)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Pat
 ients with Follicular Lymphoma (FL)\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 549335
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656221-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06656221)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Prospective\, Single-Center S
 tudy Evaluating the Efficacy and Safety of Glofitamab Combined With Orelab
 rutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma\nEs
 timated primary completion: 1 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06656221
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077723-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT04077723)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate the Safety\, Pharmacokinetics and Preliminary Anti-Tumor Act
 ivity of Englumafusp Alfa in Combination With Obinutuzumab and in Combinat
 ion With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Part
 icipants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma\nEstimated
  primary completion: 28 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04077723
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504199-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06504199)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab\, Zanubrutinib\, a
 nd Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in New
 ly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 04199
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03322865-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03322865)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab in Marginal Zone L
 ymphoma\nEstimated primary completion: January 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03322865
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03410875-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03410875)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Phase II Study of the BRAF In
 hibitor\, Vemurafenib\, Plus Obinutuzumab in Patients With Previously Untr
 eated Classical Hairy Cell Leukemia\nEstimated primary completion: January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03410
 875
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943496-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT05943496)
DESCRIPTION:Obinutuzumab\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy: 
 Tafasitamab\, Acalabrutinib\, and Obinutuzumab for the Treatment of Previo
 usly Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
 \nEstimated primary completion: 1 January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05943496
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722172-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04722172)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinut
 uzumab in People With CLL or SLL\nEstimated primary completion: February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0472217
 2
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04515238-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04515238)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Sequential Regimen of Bendamust
 ine Followed by Obinutuzumab (GA101)\, Zanubrutinib (BGB-3111) and Venetoc
 lax (ABT-199) in Patients With Relapsed/Refractory CLL\nEstimated primary 
 completion: February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04515238
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03824483)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patients With Chr
 onic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05861050-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT05861050)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: Glofitamab With Obinutuzumab\
 , Venetoclax\, and Lenalidomide for the Treatment of Patients With Newly D
 iagnosed High Risk Mantle Cell Lymphoma\nEstimated primary completion: 1 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05861050
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846623-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02846623)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Atezolizumab\, Obinutuzumab\, and Venetoclax in Treating Patients With Chr
 onic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, or Relapsed or Re
 fractory Richter Syndrome\nEstimated primary completion: 28 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02846623
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05650723)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leu
 kemia (CLL) With Response-based Obinutuzumab\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05650723
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03983954-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT03983954)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: Naptumomab Estafenatox in Combi
 nation With Durvalumab in Subjects With Selected Advanced or Metastatic So
 lid Tumor\, Including a Cohort Expansion in Esophageal Cancer.\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03983954
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624085-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06624085)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: A Study Evaluating the Safety a
 nd Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients Wit
 h Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary 
 completion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06624085
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04970901-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT04970901)
DESCRIPTION:Obinutuzumab\, phase 1\, Non-Hodgkin Lymphoma.\nStudy: A Study 
 to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine 
 in Combination With Other Anti-cancer Agents in Participants With Relapsed
  or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04970901
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04450173-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04450173)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab\, Ibrutinib\, and Venetoclax for the Treatment of Previously Untreated
  Stage II-IV Follicular Lymphoma\nEstimated primary completion: April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04450173
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847957-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07847957)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL\nEstimated primary
  completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07847957
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Safe
 ty and Preliminary Efficacy Study of CC-99282\, Alone and in Combination W
 ith Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-H
 odgkin Lymphomas (R/R NHL)\nEstimated primary completion: 7 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07674810)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotoclax\, And Obi
 nutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\
 , With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Prev
 iously Untreated CLL\nEstimated primary completion: 30 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04277637-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT04277637)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: Study of Bcl-2 Inhibitor Sonrot
 oclax (BGB-11417) in Participants With Mature B-Cell Malignancies\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04277637
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003464-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07003464)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase II Trial of Zanubrutinib\, Obinutuzumab\, Bendamustine (ZGB) as Firs
 t-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study\nEs
 timated primary completion: 1 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07003464
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513234-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06513234)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Combination of Orelabrutinib an
 d Obinutuzumab in Untreated Marginal Zone Lymphomas\nEstimated primary com
 pletion: 21 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06513234
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351527-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06351527)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: Evaluate the Safety\, Tolerabil
 ity\, Pharmacokinetics\, and Preliminary Efficacy of ICP-248 as Monotherap
 y or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Ma
 lignancies\nEstimated primary completion: 25 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06351527
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855695-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT04855695)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: Avo In R/R And Previously Unt
 reated MCL\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04855695
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959732-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06959732)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib Combined With G-CVP in Previously Untreated FL\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06959732
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04505254-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04505254)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Le
 ukemia\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04505254
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917832-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07917832)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Smart 3: A Multi-Center Phase 2
  Trial Of Golcadomide\, Glofitamab And Polatuzumab Vedotin (G2P) For Patie
 nts With Newly Diagnosed Large B-Cell Lymphoma\nEstimated primary completi
 on: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obi
 nutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07917832
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786768-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2/3 readout est. (NCT05786768)
DESCRIPTION:Obinutuzumab\, phase 2/3.\nStudy: Efficacy and Safety of Obinut
 uzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relaps
 ing Nephrotic Syndrome\nEstimated primary completion: 30 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05786768
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291220-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06291220)
DESCRIPTION:Obinutuzumab\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Bo
 dy in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphoc
 ytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06291220
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326371-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07326371)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Glofitamab Combined With CAR-T 
 Therapy in R/R DLBCL\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07326371
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04447768-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04447768)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymp
 hocytic Leukemia (CLL)\nEstimated primary completion: July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04447768
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333262-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06333262)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leuke
 mia\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06333262
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504940-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06504940)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Optimize Study - Orelabrutinib 
 Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)\nEstimated pr
 imary completion: 8 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06504940
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054776-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06054776)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Acalabrutinib\, Obinutuzumab\, 
 and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lym
 phoma\nEstimated primary completion: 13 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06054776
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzum
 ab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocyt
 ic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06071871-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06071871)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Trial of Polatuzumab Vedotin\
 , Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in L
 arge B-cell Lymphoma\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06071871
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261163-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07261163)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab\, Zanubrutinib\, a
 nd Lenalidomide in First-line Treatment of Mantle Cell Lymphoma\nEstimated
  primary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07261163
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06213311-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06213311)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Study of Axicabtagene Ciloleu
 cel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patie
 nts With Large B Cell Lymphoma\nEstimated primary completion: 31 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06213311
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265220-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06265220)
DESCRIPTION:Obinutuzumab\, phase 1\, Lupus Nephritis.\nStudy: AB-101 in Com
 bination With B-Cell Depleting mAb in Patients Who Failed Treatment for Cl
 ass III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus 
 Erythematosus\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06265220
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: Veneto
 clax\, Ibrutinib\, Prednisone\, Obinutuzumab\, and Revlimid (ViPOR) in Rel
 apsed/Refractory B-cell Lymphoma\nEstimated primary completion: 12 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT032236
 10
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744750-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07744750)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Pirtobrutinib+Sonrotoclax（PS)
  Regimen in the Treatment of B-Cell Lymphoma\nEstimated primary completion
 : 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obi
 nutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07744750
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003295-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07003295)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Testing the Anti-cancer Drug\, 
 Glofitamab\, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer
 ) Whose Disease Returned After CAR-T Cell Therapy\nEstimated primary compl
 etion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07003295
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06084936)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Study to Evaluate Glofitamab 
 as a Single Agent vs. Investigator's Choice in Participants With Relapsed/
 Refractory Mantle Cell Lymphoma\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0608493
 6
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567366-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06567366)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: CAR T-cell Therapy in Combinati
 on With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High
 -Risk Prognostic Factors\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06567366
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fi
 xed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib 
 Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic 
 Leukaemia (CLL)\nEstimated primary completion: September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561360-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06561360)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Study of Vemurafenib and Obin
 utuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Le
 ukemia (HCL)\nEstimated primary completion: 9 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06561360
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents 
 in Relapsed/Refractory Non-Hodgkin Lymphomas\nEstimated primary completion
 : 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ob
 inutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06090539
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357676-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT06357676)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: Glofitamab Plus Ibrutinib Wit
 h Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma\, I
 GNITE MCL Trial\nEstimated primary completion: 1 November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06357676
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474481-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06474481)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06474481
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940661-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06940661)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab for Remission Indu
 ction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06940661
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441954-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07441954)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: Pomalidomide Combined With Ob
 inutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent 
 Lymphoma\nEstimated primary completion: 5 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07441954
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427213-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06427213)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: This is a Phase II\, Open-label
 \, Multicentre Study of Zanubrutinib-containing Regimens in Patients With 
 Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 30 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06427213
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06916767-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06916767)
DESCRIPTION:Obinutuzumab\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or R
 efractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06916767
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04889716-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04889716)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: CAR-T Followed by Bispecific An
 tibodies\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04889716
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06108232-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06108232)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Phase 2 T
 rial of Obinutuzumab and CC-99282 for Patients With Previously Untreated H
 igh Tumor Burden Follicular Lymphoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06108232
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765317-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06765317)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Study of Glofitamab-based Tre
 atment in People With Diffuse Large B-cell Lymphoma\nEstimated primary com
 pletion: January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06765317
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480850-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07480850)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Efficacy and Safety of Glofitam
 ab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell 
 Lymphoma\nEstimated primary completion: 1 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07480850
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06192888-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280108
DTEND;VALUE=DATE:20280109
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06192888)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: A Study of Glofitamab and Lenal
 idomide in People With Mantle Cell Lymphoma\nEstimated primary completion:
  8 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06192888
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06043674)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin\, Pirto
 brutinib\, or Atezolizumab in Richter's Transformation\nEstimated primary 
 completion: 15 January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06043674
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Partic
 ipants Receiving Oral Venetoclax in Combination With Intravenously Infused
  Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06186648-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06186648)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Evaluation of Treatment by Glof
 itamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients
  With RIchter Syndrome\nEstimated primary completion: 1 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06186648
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06849713)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\, Obinutuzu
 mab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary completion: 1 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6849713
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary co
 mpletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04560322
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02629809-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02629809)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Ibrutinib\, Fludarabine Phosphate\, Cyclophosphamide\, and Obinutuzumab in
  Treating Patients With Chronic Lymphocytic Leukemia\nEstimated primary co
 mpletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02629809
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04408638)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Phase III Study Evaluating Gl
 ofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Com
 bination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refr
 actory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044
 08638
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163611-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Obinutuzumab: Phase 2/3 readout est. (NCT07163611)
DESCRIPTION:Obinutuzumab\, phase 2/3.\nStudy: Obinutuzumab Induced Decrease
 s of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study\nEstimated 
 primary completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07163611
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Time-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obinu
 tuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (C
 LL) or Richter Transformation (RT)\nEstimated primary completion: 25 April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05536
 349
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07299149)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of U
 ntreated Follicular Lymphoma\nEstimated primary completion: 28 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07299149
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558604-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06558604)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Phase II Study of Glofitamab Wi
 th Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma\nEstimate
 d primary completion: May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06558604
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to O
 binutuzumab and Venetoclax in Previously Untreated Patients With High Risk
  CLL\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918015-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06918015)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib Plus GCVP (Obinutuzumab\, Cyclophosphamide\, Vindesine\, Prednisolone)
  in Previously Untreated Follicular Lymphoma\nEstimated primary completion
 : 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06918015
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Assessing the Ability of Combination Treatment With Venetoclax to Permit T
 ime Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary com
 pletion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03701282
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268521-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07268521)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Multicenter Phase 2 Single-ar
 m Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab
  in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Ref
 ractory or Intolerant to Rituximab\nEstimated primary completion: 31 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0726852
 1
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06781944-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06781944)
DESCRIPTION:Obinutuzumab\, phase 3\, Primary Membranous Nephropathy.\nStudy
 : OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membra
 nous Nephropathy(Blossom Study)\nEstimated primary completion: 31 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06781944
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039619-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05039619)
DESCRIPTION:Obinutuzumab\, phase 2\, Lupus Nephritis.\nStudy: A Study to Ev
 aluate the Efficacy\, Safety\, and Pharmacokinetics of Obinutuzumab in Ado
 lescents With Active Class III or IV Lupus Nephritis and the Safety and PK
  of Obinutuzumab in Pediatric Participants\nEstimated primary completion: 
 15 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05039619
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710157-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07710157)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Trial to Assess the Efficacy 
 and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease 
 (MCD)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07710157
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05100862-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05100862)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: A Study o
 f Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Partic
 ipants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05100862
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Tr
 eatment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leuke
 mia or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04169737
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126678-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Obinutuzumab: Phase na readout est. (NCT07126678)
DESCRIPTION:Obinutuzumab\, phase na\, Follicular Lymphoma.\nStudy: Fixed-Du
 ration Zanubrutinib\, Bendamustine\, and Obinutuzumab (ZBG) in Treatment-N
 aïve Advanced Stage Follicular Lymphoma\nEstimated primary completion: 15
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07126678
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252675-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06252675)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Glofitamab With Pirtobrutinib f
 or Relapsed or Refractory Mantle Cell Lymphoma\nEstimated primary completi
 on: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obi
 nutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06252675
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06867536-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06867536)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Hypofractionation Radiotherapy 
 in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymph
 oma With Baseline High Tumor Burden\nEstimated primary completion: 31 Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 67536
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799220-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07799220)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Study of Zanubrutinib\, Obinu
 tuzumab\, and Sonrotoclax in People With Mantle Cell Lymphoma\nEstimated p
 rimary completion: September 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07799220
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624799-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07624799)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immu
 no-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chro
 nic Lymphocytic Leukemia (CLL).\nEstimated primary completion: 1 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07624
 799
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649812-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06649812)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Testing the Effectiveness of a 
 Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Ref
 ractory Aggressive B-cell Lymphoma\nEstimated primary completion: 1 Septem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 649812
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06175000-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06175000)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Maintenance Obinutuzumab in Tre
 ating Patients With Central Nervous System Lymphoma Who Have Achieved a Co
 mplete or Partial Response\nEstimated primary completion: 15 September 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06175000
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711483-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07711483)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: GLORY: Glofit-GemOx With Liso-C
 el For Lymphoma\nEstimated primary completion: 15 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07711483
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107490-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT07107490)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: A PHASE I STUDY OF ALPS12 IN PA
 TIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER\nEstimated primary comp
 letion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07107490
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883135-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07883135)
DESCRIPTION:Obinutuzumab\, phase 2\, Non-Hodgkin Lymphoma.\nStudy: Bispecif
 ic Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Ce
 ll Lymphomas\nEstimated primary completion: 1 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07883135
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04269902-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04269902)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Le
 ukemia (CLL) or Small Lymphocytic Leukemia (SLL)\, EVOLVE CLL/SLL Study\nE
 stimated primary completion: 1 October 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04269902
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613788-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07613788)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Rimegepant Plus Glofitamab and 
 CD19 CAR-T Therapy in R/R LBCL\nEstimated primary completion: November 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07613788
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03516617-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281111
DTEND;VALUE=DATE:20281112
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03516617)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early
 -Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimat
 ed primary completion: 11 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03516617
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888621-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07888621)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Glofitamab Plus Gemcitabine and
  Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Centr
 al Nervous System Lymphoma\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07888621
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634589-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281202
DTEND;VALUE=DATE:20281203
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT06634589)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: A Study to Investigate Safety
  and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other A
 gents in Participants With Relapsed or Refractory B-Cell Malignancies\nEst
 imated primary completion: 2 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06634589
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07240194-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07240194)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: The Efficacy and Safety of Glof
 itamab in Combination With PD-1 Antibody and Lenalidomide in Patients With
  Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A
  Prospective\, Multicenter\, Phase II Clinical Study\nEstimated primary co
 mpletion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07240194
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165769-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07165769)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Zanubrutinib\, Obinutuzumab\, a
 nd Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell L
 ymphoma With Prominent Nucleoli (SBLPN): A Prospective\, Open-label\, Sing
 le-arm Clinical Trial\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07165769
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793189-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06793189)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: MZL-IPI Risk-adapted Targeted T
 herapy in Untreated MZL\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06793189
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774234-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07774234)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Sonrotoclax\, Glofitamab\, Gemc
 itabine\, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07774234
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922604-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06922604)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: Glofitamab With Obinutuzumab Pr
 e-treatment for the Treatment of Central Nervous System Lymphoma\nEstimate
 d primary completion: 2 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06922604
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767188-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT07767188)
DESCRIPTION:Obinutuzumab\, phase 3\, Lupus Nephritis.\nStudy: A Trial to Ex
 plore the Efficacy and Safety of O-triple as Initial Therapy in the Active
  Lupus Nephritis Patients (INITIAL Trial)\nEstimated primary completion: 2
 7 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07767188
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233330-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07233330)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab in Adult Rituximab
 -Dependent Nephrotic Syndrome\nEstimated primary completion: March 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07233330
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548255-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT07548255)
DESCRIPTION:Obinutuzumab\, phase 1.\nStudy: The Efficacy and Safety of Sonr
 otoclax\, Zanubrutinib Combined With Obinutuzumab in MCL\nEstimated primar
 y completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07548255
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611214-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:Obinutuzumab: Phase 4 readout est. (NCT07611214)
DESCRIPTION:Obinutuzumab\, phase 4\, Lupus Nephritis.\nStudy: PRESERVE: LUP
 KYNIS in Combination With Belimumab\, Obinutuzumab or Anifrolumab in Patie
 nts With Lupus Nephritis\nEstimated primary completion: 2 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07611214
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03075696-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03075696)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Dose
  Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combi
 nation With Obinutuzumab\, Administered After a Fixed\, Single Pre-treatme
 nt Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell No
 n-hodgkin's Lymphoma\nEstimated primary completion: 30 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03075696
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05169515-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT05169515)
DESCRIPTION:Obinutuzumab\, phase 1\, Non-Hodgkin Lymphoma.\nStudy: A Study 
 Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab o
 r Glofitamab in Combination With CC-220 and/or CC-99282 in Participants Wi
 th B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05169515
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978088-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06978088)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic
  Lymphoma (CLL/SLL) and Variants of This\nEstimated primary completion: 1 
 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6978088
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218510-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290608
DTEND;VALUE=DATE:20290609
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07218510)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of U
 ntreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma\, Lon
 GEVity Trial\nEstimated primary completion: 8 June 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07218510
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719556-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07719556)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Orelabrutinib Combined With Obi
 nutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Ma
 ntle Cell Lymphoma (MCL)\nEstimated primary completion: 1 July 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07719556
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806033-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06806033)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Evaluate Optimization of CRS Pr
 ofile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL\nEst
 imated primary completion: 31 July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06806033
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721363-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290902
DTEND;VALUE=DATE:20290903
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07721363)
DESCRIPTION:Obinutuzumab\, phase 2\, Lupus Nephritis.\nStudy: Obinutuzumab 
 for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II T
 rial\nEstimated primary completion: 2 September 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07721363
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06943872)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obi
 nutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Ritu
 ximab Treatment In Patients With Relapsed and/or Refractory Chronic Lympho
 cytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEstimated pri
 mary completion: 30 September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy i
 n Pediatric and Young Adult Participants With Relapsed/Refractory Mature B
 -Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842523-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07842523)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Obinutuzumab in Systemic Sclero
 sis\nEstimated primary completion: December 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07842523
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Ly
 mphocytic Leukemia\nEstimated primary completion: 1 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502872-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07502872)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: TPG: Tafasitamab\, Polatuzumab 
 Vedotin\, and Glofitamab as First-line Therapy for Diffuse Large B-cell Ly
 mphoma and High-grade B-cell Lymphoma\nEstimated primary completion: 1 Jan
 uary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7502872
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07696377-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20300130
DTEND;VALUE=DATE:20300131
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07696377)
DESCRIPTION:Obinutuzumab\, phase 1/2.\nStudy: An Exploratory Study of Obinu
 tuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradi
 culoneuropathy\nEstimated primary completion: 30 January 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07696377
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719855-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT07719855)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: A Multice
 nter\, Prospective\, Open-Label\, Randomized Controlled Clinical Study of 
 Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzu
 mab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma\nEstimated p
 rimary completion: July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07719855
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599423-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07599423)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Study of Glofitamab Plus GemO
 x Compared With Standard of Care in Patients With Relapsed/Refractory Diff
 use Large B-Cell Lymphoma\nEstimated primary completion: 21 July 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07599423
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961500-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06961500)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Ne
 wly Diagnosed Follicular Lymphoma Grade 3A\nEstimated primary completion: 
 1 November 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06961500
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929222-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05929222)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: Compariso
 n Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early 
 Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana L
 infomi\nEstimated primary completion: April 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05929222
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (PV
 O) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic 
 Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary completi
 on: 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06967610
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887061-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07887061)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Tacabrutideg and Sonrotoclax\, With Response-Guided Obinutuzumab\, for the
  Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphom
 a (SLL)\nEstimated primary completion: 1 July 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07887061
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634289-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07634289)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Radiotherapy in Combination Wit
 h Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma\nEstimat
 ed primary completion: December 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07634289
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824701-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Obinutuzumab: Phase 1 readout est. (NCT06824701)
DESCRIPTION:Obinutuzumab\, phase 1\, Non-Hodgkin Lymphoma.\nStudy: Tazemeto
 stat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in
  Relapsed or Refractory B-cell Non-Hodgkin Lymphoma\nEstimated primary com
 pletion: January 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06824701
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833763-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05833763)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: A Phase 2 Trial of GlOfitamab a
 nD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor
  Exposure.\nEstimated primary completion: April 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05833763
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544785-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06544785)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocy
 tic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary completion: 
 31 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06544785
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Study of NX-5948 in Combination With Other Agents in Adults With B-cell 
 Malignancies\nEstimated primary completion: May 2033. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724457-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Obinutuzumab: Phase 2/3 readout est. (NCT07724457)
DESCRIPTION:Obinutuzumab\, phase 2/3.\nStudy: Testing the Addition of a New
  Anti-Cancer Drug\, Glofitamab to Usual Chemotherapy for Burkitt and Doubl
 e Hit Lymphoma\nEstimated primary completion: 1 November 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07724457
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-2649@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Previously Untreated Follicular Lymphoma\nEst
 imated primary completion: November 2037. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
